Italia markets closed

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
11,26-0,27 (-2,34%)
Alla chiusura: 04:00PM EST
11,41 +0,15 (+1,33%)
Dopo ore: 05:29PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente11,53
Aperto11,09
Denaro11,27 x 800
Lettera11,29 x 1100
Min-Max giorno10,99 - 11,93
Intervallo di 52 settimane7,70 - 21,59
Volume2.553.732
Media Volume2.003.527
Capitalizzazione774,271M
Beta (5 anni mensile)1,87
Rapporto PE (ttm)N/D
EPS (ttm)-2,73
Prossima data utili22 feb 2023 - 27 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A14,24
  • GlobeNewswire

    Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies

    Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for AsCas12a Shoreline to acquire Editas Medicine’s iNK cell franchise, including EDIT-202 and certain related manufacturing technologies Economics to Editas Medicine to include upfront payment, and development and commercial milestone and royalty payments CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (

  • GlobeNewswire

    Editas Medicine Announces Strategic Updates and Portfolio Reprioritization

    Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing Discontinuing internal investments in inherited retinal diseases and in preclinical wholly owned iNK programs Mark S. Shearman, Ph.D., Chief Scientific Officer to step down, departing March 31 Reprioritization reduces workforce by approximately 20%, expected to extend cash runway into 2025 Company to present at the 41st Annual J.P. Morgan Healthcare Conference January 10 CAMBRIDGE, Mass., Jan. 09, 202

  • GlobeNewswire

    Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA. A live webcast of the presentation will be available on the “Investors” section of the Editas Medicine website at www.editasmedicine.com.